NY A09535

Establishes a generic drug research and development laboratory and production facility within the State University of New York system to produce and distribute generic prescription drugs.

Generic drugs produced must be priced at or below the cost of production for New York residents.

Prioritizes development of generic drugs with the greatest impact on lowering drug costs, increasing market competition, addressing shortages, and improving public health.

Creates the Empire State Biosimilar Insulin Initiative as the first priority, requiring production of generic forms of the three most widely used insulins through a non-profit FDA-registered manufacturer.

Requires insulin produced under the initiative to be available at a price not to exceed $30 per monthly dose for New York residents, with interim partnerships to begin distribution before the facility is completed.